FindTrial
Sign In

VK-2019

DRUG3 trials

Sponsors

Cullinan Therapeutics Inc., Stanford University, Pierluigi Porcu

Conditions

Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) InfectionEpstein-Barr Virus Related CarcinomaNasopharyngeal CancerNasopharyngeal Carcinoma

Phase 1

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
TerminatedNCT03682055
Cullinan Therapeutics Inc.Nasopharyngeal Cancer, Nasopharyngeal Carcinoma
Start: 2019-04-04End: 2020-08-08Updated: 2023-08-15
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
RecruitingNCT06789159
Pierluigi PorcuDiffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection
Start: 2026-08-21End: 2028-10-01Target: 30Updated: 2026-09-02

Phase 2

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Active, not recruitingNCT04925544
Stanford UniversityEpstein-Barr Virus Related Carcinoma, Nasopharyngeal Cancer
Start: 2022-01-25End: 2027-06-17Updated: 2026-06-24

Related Papers

Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus–positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
Journal of Clinical Oncology2023-06-014 citations